BioCentury
ARTICLE | Financial News

Immuno-oncology play Arcus raises $107M

November 14, 2017 12:01 AM UTC

Immuno-oncology company Arcus Biosciences (Hayward, Calif.) raised $107 million in a untranched series C round led by existing investor GV.

New investors Wellington Management, EcoR1 Capital, BVF Partners, Decheng Capital, Hillhouse, Aisling Capital and Leerink Partners also participated, along with existing investors The Column Group, Foresite Capital, Invus Opportunities, DROIA, Celgene Corp. (NASDAQ:CELG) and Taiho Ventures...